STMP1 Protein Linked to Mitochondrial Protection in Aging Hearts

Discovery of STMP1’s Role in Heart Health

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore, have identified the short mitochondrial protein STMP1 as important for maintaining heart muscle cell health during aging.

STMP1, which is made up of 47 amino acids, helps preserve the structure of mitochondria in cardiomyocytes—the cells responsible for heart contractions.

Preclinical Evidence and Mechanism

The findings, published in Circulation, are based on laboratory models and human heart tissue analysis. In these studies, STMP1 levels were found to be lower in aging hearts and in human hearts with dilated cardiomyopathy.

Laboratory models lacking STMP1 developed mitochondrial damage, chronic inflammation, reduced heart pumping ability, heart enlargement, scarring, and heart muscle cell death. Restoring STMP1 or blocking the related inflammation pathway early helped preserve heart function.

How STMP1 Loss Triggers Inflammation

Advanced 3D electron microscopy revealed that loss of STMP1 disrupts the inner mitochondrial membrane (cristae), causing mitochondrial DNA to leak into the cell.

This DNA leakage activates the cGAS–STING immune pathway, leading to persistent inflammation and further damage to heart muscle cells. Signs of inflammation appeared before overt heart failure in laboratory models, suggesting inflammation may contribute directly to disease progression.

Potential Implications for Metabolic Health

Heart failure is a leading cause of illness and death in older adults, often linked to chronic low-grade inflammation (inflammaging). The study suggests that maintaining STMP1 levels could help protect against age-related heart decline by stabilizing mitochondrial structure and reducing inflammation.

The research remains at the preclinical stage, and further studies are needed to determine if these findings will translate to humans. STMP1 could become a future biomarker or treatment target for identifying or managing heart failure risk.

Limitations and Next Steps

The current findings are based on laboratory models and human tissue samples. No clinical trials in humans have yet been conducted.

Researchers plan to test STMP1 restoration and inflammation-blocking treatments in larger and more disease-relevant models and to explore whether STMP1 levels can be measured as an early warning sign for heart failure risk.